BioNTech hit with 'notice of default' from NIH in COVID-19 vaccine royalty dispute
Fierce Pharma
MARCH 25, 2024
officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine. Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S.
Let's personalize your content